Hematopathology — MCQs

Hematopathology Indian Medical PG Practice Questions and MCQs

Question 211: A 40-year-old male who underwent splenectomy 20 years ago presents for a peripheral blood smear examination. What would be observed?

A. Dohle bodies
B. Hypersegmented neutrophils
C. Spherocytes
D. Howell-Jolly bodies (Correct Answer)

Explanation: ### Explanation **Correct Answer: D. Howell-Jolly bodies** **Mechanism:** Howell-Jolly bodies are small, round, basophilic nuclear remnants (DNA clusters) normally found in maturing erythrocytes [1]. In a healthy individual, the **splenic macrophages** (pitting function) identify and remove these inclusions as RBCs pass through the splenic cords. Following a **splenectomy** (or in states of functional asplenia like Sickle Cell Anemia), this filtering mechanism is lost, allowing these inclusions to persist in the peripheral circulation [1], [2]. **Analysis of Incorrect Options:** * **A. Dohle bodies:** These are light blue, peripheral cytoplasmic inclusions in neutrophils composed of dilated rough endoplasmic reticulum. They are markers of **leukemoid reactions**, severe infections, or burns, not asplenia. * **B. Hypersegmented neutrophils:** Defined as neutrophils with $\geq$ 6 lobes or $>5\%$ with 5 lobes. These are pathognomonic for **Megaloblastic anemia** (Vitamin B12 or Folate deficiency). * **C. Spherocytes:** These are small, dense RBCs lacking central pallor [3]. They are seen in **Hereditary Spherocytosis** or Immune Hemolytic Anemia [3], [4]. Post-splenectomy, one actually expects to see **Target cells** (due to relative membrane excess). **High-Yield Clinical Pearls for NEET-PG:** * **Post-Splenectomy Blood Picture:** Look for Howell-Jolly bodies, **Pappenheimer bodies** (iron granules), **Heinz bodies** (denatured hemoglobin), and **Target cells** [2]. * **Transient Findings:** Thrombocytosis and leukocytosis are common immediately post-surgery but usually normalize over time. * **Infection Risk:** Patients are at lifelong risk of sepsis from **encapsulated organisms** (*S. pneumoniae, H. influenzae, N. meningitidis*); vaccination is mandatory. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 644-645. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 578-579. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 597-598. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 602-603.

Question 212: Stem cells show positivity with which of the following markers?

A. CD19
B. CD3
C. CD34 (Correct Answer)
D. CD38

Explanation: **Explanation:** The correct answer is **CD34**. **1. Why CD34 is correct:** CD34 is a transmembrane phosphoglycoprotein primarily expressed on **hematopoietic stem cells (HSCs)** and progenitor cells [1]. It acts as a cell-cell adhesion factor, helping stem cells attach to the bone marrow extracellular matrix or stromal cells. As these cells mature and differentiate into specific lineages, the expression of CD34 is lost. Therefore, CD34 is the gold-standard marker used in flow cytometry to quantify stem cells for **Hematopoietic Stem Cell Transplantation (HSCT)** and to identify blasts in **Acute Leukemias** [1]. **2. Why the other options are incorrect:** * **CD19:** This is a definitive marker for the **B-cell lineage**. It is expressed from the early pro-B cell stage through terminal differentiation into plasma cells (though expression is lost in mature plasma cells). * **CD3:** This is the most specific marker for **T-cells**. It is part of the T-cell receptor (TCR) complex and is expressed on all mature T-lymphocytes. * **CD38:** While found on many immune cells, high expression of CD38 is characteristic of **Plasma cells**. In the context of stem cells, "CD34+ CD38–" is the signature for the most primitive, multipotent hematopoietic stem cells. **High-Yield Clinical Pearls for NEET-PG:** * **Stem Cell Harvest:** A minimum dose of **2 x 10⁶ CD34+ cells/kg** of the recipient's body weight is typically required for successful engraftment [1]. * **Acute Leukemia:** The presence of >20% blasts (often CD34+) in the bone marrow is diagnostic of Acute Leukemia (AML/ALL). * **Other CD34+ cells:** Besides HSCs, CD34 is also expressed by **vascular endothelial cells** and is used as a marker for vascular tumors (e.g., Angiosarcoma, Kaposi Sarcoma). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 584-586.

Question 213: What is the most common variant of lymphoma seen in HIV-positive patients?

A. Immunoblastic Lymphoma (Correct Answer)
B. Burkitt's Lymphoma
C. Primary CNS Lymphoma
D. Mantle Cell Lymphoma

Explanation: **Explanation:** The risk of developing Non-Hodgkin Lymphoma (NHL) is significantly higher in HIV-positive patients due to chronic B-cell stimulation, immune dysregulation, and the oncogenic role of viruses like EBV and HHV-8 [1]. **Why Immunoblastic Lymphoma is correct:** HIV-associated lymphomas are predominantly high-grade B-cell lymphomas [2]. Among these, **Diffuse Large B-Cell Lymphoma (DLBCL)** is the most common histological subtype [4]. DLBCL is further categorized into two morphological variants: **Centroblastic** and **Immunoblastic**. In the context of HIV, the **Immunoblastic variant** is the most frequently encountered subtype. It typically occurs in patients with more advanced immunosuppression (lower CD4 counts) and has a strong association with EBV infection [1]. **Analysis of Incorrect Options:** * **B. Burkitt’s Lymphoma:** This is the second most common variant. Unlike the immunoblastic subtype, Burkitt’s lymphoma often occurs in patients with relatively preserved CD4 counts (>200 cells/µL) and is characterized by the *c-myc* translocation. * **C. Primary CNS Lymphoma (PCNSL):** While PCNSL is an AIDS-defining illness and is almost 100% associated with EBV, it is less common than systemic DLBCL/Immunoblastic lymphoma. * **D. Mantle Cell Lymphoma:** This is a mature B-cell neoplasm typically seen in older adults and is not specifically associated with HIV infection. **High-Yield Clinical Pearls for NEET-PG:** * **Most common malignancy in HIV:** Kaposi Sarcoma (caused by HHV-8) [3]. * **Most common hematological malignancy in HIV:** Non-Hodgkin Lymphoma (specifically DLBCL, Immunoblastic variant). * **Body Cavity Lymphoma:** Also known as Primary Effusion Lymphoma (PEL), it is caused by HHV-8 and presents as malignant effusions without a solid tumor mass [4]. * **EBV Association:** Nearly 100% of HIV-associated PCNSL and ~80-90% of Immunoblastic lymphomas are EBV-positive [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 261-263. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 595-596. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of the Immune System, pp. 261-262. [4] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 604-605.

Question 214: In a patient with acute leukemia, the immunophenotype pattern is CD 19+ve, CD 10+ve, CD33+ve, and CD 13+ve. What is the probable diagnosis?

A. Biphenotypic leukemia (Correct Answer)
B. Acute lymphoblastic leukemia (ALL)
C. Acute myeloid leukemia - M2 subtype (AML-M2)
D. Acute myeloid leukemia - M0 subtype (AML-M0)

Explanation: ### Explanation **1. Why Biphenotypic Leukemia is Correct:** Biphenotypic Acute Leukemia (BAL), now classified under **Mixed Phenotype Acute Leukemia (MPAL)** by the WHO, occurs when a single population of blasts expresses markers of more than one lineage. In this case, the blasts express **B-lymphoid markers (CD19, CD10)** and **Myeloid markers (CD33, CD13)**. According to the scoring system (EGIL) or WHO criteria, the co-expression of strong lineage-specific markers from two different lineages (B-cell and Myeloid) confirms a mixed phenotype rather than a lineage-restricted leukemia. **2. Why Incorrect Options are Wrong:** * **B. Acute Lymphoblastic Leukemia (ALL):** While CD19 and CD10 are classic B-ALL markers, the significant expression of CD33 and CD13 (myeloid markers) excludes a diagnosis of pure ALL. * **C. AML-M2:** This is a myeloid leukemia characterized by the t(8;21) translocation. While it may occasionally show "lineage infidelity" (like CD19 expression), the presence of strong B-cell markers (CD10/CD19) alongside myeloid markers in a blast population points toward MPAL. * **D. AML-M0:** This is minimally differentiated AML. Blasts are negative for myeloperoxidase (MPO) and typically do not express lymphoid markers like CD10 or CD19. **3. High-Yield Clinical Pearls for NEET-PG:** * **MPAL Definition:** Requires meeting specific criteria for more than one lineage (e.g., MPO for Myeloid; CD19/CD22/CD79a for B-lineage; cytoplasmic CD3 for T-lineage). * **Common Translocations:** MPAL is frequently associated with **t(9;22)** (Philadelphia chromosome) or **MLL gene rearrangements** (11q23). * **Prognosis:** Generally carries a **poorer prognosis** compared to lineage-specific AML or ALL. * **CD10 (CALLA):** A high-yield marker for Common ALL, but its presence alongside myeloid markers is a hallmark of biphenotypic presentation.

Question 215: All are true about hemophilia, except?

A. Increased bleeding time (BT) (Correct Answer)
B. Decreased factor VIII
C. Decreased factor IX
D. Increased partial thromboplastin time (PTT)

Explanation: Explanation Hemophilia is a group of hereditary bleeding disorders caused by deficiencies in specific clotting factors [1]. To answer this question, one must distinguish between primary hemostasis (platelet plug formation) and secondary hemostasis (coagulation cascade). 1. Why "Increased Bleeding Time (BT)" is the correct answer (The Exception): Bleeding Time (BT) is a measure of platelet function and primary hemostasis. In Hemophilia, platelets are normal in number and function; the defect lies solely in the coagulation cascade (secondary hemostasis). Therefore, BT remains normal in Hemophilia. An increased BT would instead suggest conditions like Von Willebrand Disease (vWD) or thrombocytopenia. 2. Analysis of Incorrect Options: * Decreased Factor VIII (Option B): This is the hallmark of Hemophilia A (Classic Hemophilia), which accounts for about 80% of cases [1]. Factor VIII takes part in the coagulation cascade as a cofactor in the activation of factor X [2]. * Decreased Factor IX (Option C): This defines Hemophilia B (Christmas Disease). Both Hemophilia A and B are X-linked recessive disorders with identical clinical presentations [1]. * Increased Partial Thromboplastin Time (PTT) (Option D): Factors VIII and IX are part of the intrinsic pathway. A deficiency in either will prolong the Activated Partial Thromboplastin Time (aPTT). Clinical Pearls for NEET-PG: * Inheritance: X-linked recessive (affects males; females are usually asymptomatic carriers, though unfavorable lyonization can occur) [1]. * Clinical Feature: Characterized by deep tissue bleeding, most notably hemarthrosis (bleeding into joints) and hematomas. * Lab Profile: Normal BT, Normal PT, Normal Platelet Count, but Prolonged aPTT. * Mixing Study: In Hemophilia, the prolonged aPTT corrects when mixed with normal plasma. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 670-671. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 669-670.

Question 216: Which of the following statements is true about Multiple Myeloma?

A. Monoclonal immunoglobulin (M spike) is increased. (Correct Answer)
B. Plasma cells deposit directly in glomerular capillaries, causing kidney damage.
C. Interleukin-8 (IL-8) is a marker for bone lesions.
D. Alkaline phosphatase levels are invariably increased.

Explanation: **Explanation:** **1. Why Option A is Correct:** Multiple Myeloma (MM) is a neoplastic proliferation of a single clone of plasma cells [1]. These malignant cells secrete a monoclonal immunoglobulin or its fragments (light chains) [2]. On serum protein electrophoresis (SPEP), this results in a sharp, narrow peak in the gamma-globulin region known as the **M-protein (M-spike)** [1]. This is the hallmark diagnostic feature of the disease. **2. Why the Other Options are Incorrect:** * **Option B:** Kidney damage in MM is primarily caused by **"Myeloma Kidney" (Cast Nephropathy)**. This occurs when filtered free light chains (Bence-Jones proteins) precipitate with Tamm-Horsfall protein in the distal tubules, forming obstructive casts [3]. It is not due to direct plasma cell deposition in glomerular capillaries. * **Option C:** **Interleukin-6 (IL-6)**, not IL-8, is the key cytokine in MM. It acts as a major growth factor for plasma cells and stimulates osteoclasts. Bone lesions are mediated by **RANKL** activation. * **Option D:** In MM, bone lesions are purely **osteolytic** ("punched-out" lesions) [4] with no osteoblastic activity. Therefore, **Alkaline Phosphatase (ALP) levels are typically normal**, which helps differentiate MM from bony metastases or Paget’s disease where ALP is elevated. **NEET-PG High-Yield Pearls:** * **CRAB Criteria:** Clinical features include **C**alcium (high), **R**enal failure, **A**nemia, and **B**one lesions [1]. * **Blood Smear:** Characterized by **Rouleaux formation** due to increased globulins decreasing the zeta potential of RBCs [3]. * **Diagnosis:** Bone marrow biopsy showing **>10% clonal plasma cells** is a major diagnostic criterion [4]. Look for "Mott cells" or "Flame cells" in the marrow. * **Urine:** Bence-Jones proteins are detected by the heat precipitation test (precipitate at 40-60°C, redissolve at 100°C) [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 616-617. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 608-609. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 607-608. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 617-618.

Question 217: All of the following can cause megakaryocytic thrombocytopenia, except?

A. Idiopathic thrombocytopenic purpura
B. Systemic lupus erythematosus
C. Aplastic anemia (Correct Answer)
D. Disseminated intravascular coagulation (DIC)

Explanation: To understand this question, we must differentiate between **Megakaryocytic** and **Amegakaryocytic** thrombocytopenia. ### **The Core Concept** * **Megakaryocytic Thrombocytopenia:** Occurs when there is peripheral destruction or consumption of platelets. The bone marrow is healthy and responds by increasing the number of megakaryocytes (hyperplasia) to compensate for the low platelet count [2]. * **Amegakaryocytic Thrombocytopenia:** Occurs when the primary defect lies in the bone marrow production. There is a lack of precursor cells (megakaryocytes) [1]. ### **Why Aplastic Anemia is the Correct Answer** **Aplastic Anemia** is a state of bone marrow failure characterized by pancytopenia and a hypocellular marrow [3]. Since the hematopoietic stem cells are damaged or destroyed, there is a **marked decrease or absence of megakaryocytes** in the marrow [1]. Therefore, it causes *amegakaryocytic* thrombocytopenia. ### **Analysis of Incorrect Options** * **A. Idiopathic Thrombocytopenic Purpura (ITP):** This is an autoimmune condition where anti-platelet antibodies cause peripheral destruction in the spleen. The marrow shows increased megakaryocytes (compensatory) [4]. * **B. Systemic Lupus Erythematosus (SLE):** Similar to ITP, SLE often causes immune-mediated peripheral destruction of platelets, leading to a megakaryocytic marrow [1]. * **D. Disseminated Intravascular Coagulation (DIC):** This is a consumption coagulopathy. Platelets are "used up" in widespread microthrombi. The marrow remains functional and increases megakaryocyte production to meet demand. ### **NEET-PG High-Yield Pearls** * **Bone Marrow in ITP:** Characterized by "Megakaryocytic Hyperplasia" with many immature forms (e.g., smooth-bordered megakaryocytes) [4]. * **Other causes of Megakaryocytic Thrombocytopenia:** Hypersplenism, TTP (Thrombotic Thrombocytopenic Purpura), and Mechanical heart valves. * **Other causes of Amegakaryocytic Thrombocytopenia:** Leukemia, Myelodysplastic Syndrome (MDS), and Vitamin B12/Folate deficiency (ineffective thrombopoiesis) [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 665-666. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 666-667. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 662-663. [4] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 620-621.

Question 218: Which of the following factors is NOT involved in the intrinsic pathway of coagulation?

A. Factor XII
B. Factor XI
C. Factor IX
D. Factor VII (Correct Answer)

Explanation: The coagulation cascade is divided into the intrinsic, extrinsic, and common pathways. Understanding the specific factors involved in each is a high-yield topic for NEET-PG. ### **Explanation of the Correct Answer** **Factor VII (Option D)** is the correct answer because it is the primary component of the **Extrinsic Pathway**. The extrinsic pathway is triggered by vascular injury, which releases **Tissue Factor (Factor III)** [1]. Tissue Factor then binds with Factor VII to form a complex that activates Factor X, entering the common pathway [1]. ### **Analysis of Incorrect Options** The **Intrinsic Pathway** (Contact Activation Pathway) involves factors that are present within the circulating blood. It is triggered when blood comes into contact with subendothelial collagen or negatively charged surfaces. * **Factor XII (Hageman Factor):** The starting point of the intrinsic pathway; it is activated upon contact with collagen. * **Factor XI (Plasma Thromboplastin Antecedent):** Activated by Factor XIIa. * **Factor IX (Christmas Factor):** Activated by Factor XIa. It then works with Factor VIIIa to activate Factor X. ### **High-Yield Clinical Pearls for NEET-PG** Mnemonic for Intrinsic Pathway: "TENET" (Twelve, Eleven, Nine, Eight, Ten). * **Monitoring:** The **aPTT** (activated Partial Thromboplastin Time) measures the Intrinsic and Common pathways, while **PT** (Prothrombin Time) measures the Extrinsic and Common pathways [3]. * **Vitamin K Dependent Factors:** II, VII, IX, and X [1]. Factor VII has the **shortest half-life**, making PT the first lab value to prolong in early liver disease or Vitamin K deficiency [1]. * **Hemophilia A & B:** These involve deficiencies in Factors VIII and IX respectively [2], both of which are part of the intrinsic pathway, leading to a prolonged aPTT. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 582-583, 624-625. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 623-624. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 625-626.

Question 219: Delayed prolonged bleeding after a minor surgery is caused by a defect in which of the following?

A. Primary hemostasis.
B. Secondary hemostasis. (Correct Answer)
C. Defect in the capillary bed to support the clot.
D. Defect in connective tissue to support capillaries.

Explanation: **Explanation:** The clinical presentation of **delayed, prolonged bleeding** after a minor procedure is the hallmark of a defect in **Secondary Hemostasis** [1]. 1. **Why Secondary Hemostasis is correct:** Secondary hemostasis involves the coagulation cascade, which results in the formation of a stable **fibrin mesh** to reinforce the initial platelet plug [1]. In disorders like Hemophilia (Factor VIII or IX deficiency), primary hemostasis is intact, so the initial "plug" forms and bleeding stops temporarily [2]. However, because the plug is not stabilized by fibrin, it easily dislodges or dissolves, leading to characteristic **delayed re-bleeding** [1], [2]. 2. **Why other options are incorrect:** * **Primary Hemostasis:** Defects here (e.g., Von Willebrand Disease, Thrombocytopenia) typically present with **immediate** bleeding after injury, characterized by petechiae, ecchymosis, and mucosal bleeding (epistaxis, gingival bleeding). * **Defects in Capillary Bed/Connective Tissue:** These are vascular purpuras (e.g., Scurvy, Ehlers-Danlos syndrome). While they cause easy bruising and skin fragility, they do not typically present with the classic "delayed" bleeding pattern seen in coagulation factor deficiencies. **High-Yield Clinical Pearls for NEET-PG:** * **Primary Hemostasis Defect:** Immediate bleeding, superficial (skin/mucosa), petechiae present. * **Secondary Hemostasis Defect:** Delayed bleeding, deep-seated (hemarthrosis, muscle hematomas), petechiae absent [3]. * **Post-Extraction Bleeding:** If a patient bleeds immediately after a tooth extraction, think Platelets (Primary); if they stop bleeding but start again a few hours later, think Coagulation Factors (Secondary). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Hemodynamic Disorders, Thromboembolic Disease, and Shock, pp. 126-128. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 670-671. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 623-625.

Question 220: All of the following are WHO classified Myelodysplastic Syndromes except:

A. Chronic myeloid leukemia (CML) (Correct Answer)
B. Refractory anemia with excess blasts
C. Refractory anemia with ringed sideroblasts
D. Refractory anemia

Explanation: **Explanation:** The correct answer is **Chronic myeloid leukemia (CML)** because it is classified as a **Myeloproliferative Neoplasm (MPN)**, not a Myelodysplastic Syndrome (MDS) [1]. **1. Why CML is the correct answer:** MDS and MPN are distinct categories in the WHO classification of myeloid neoplasms. * **MDS** is characterized by ineffective hematopoiesis, resulting in **cytopenias** (low blood counts) and dysplastic morphological changes in the bone marrow [2]. * **MPN (including CML)** is characterized by the overproduction of one or more formed elements (leukocytosis, thrombocytosis) with effective hematopoiesis. CML is specifically defined by the presence of the **Philadelphia chromosome t(9;22)** and the *BCR-ABL1* fusion gene [1]. **2. Why the other options are incorrect:** Options B, C, and D are classic subtypes of MDS according to the WHO classification (though nomenclature has evolved in the 2022 update to "MDS with low blasts" or "MDS with ring sideroblasts"): * **Refractory Anemia (RA):** MDS with dysplasia limited to the erythroid lineage and <5% blasts. * **Refractory Anemia with Ringed Sideroblasts (RARS):** MDS where >15% of erythroid precursors are ring sideroblasts. * **Refractory Anemia with Excess Blasts (RAEB):** MDS with increased myeloblasts (5-19%) in the marrow, representing a more aggressive stage. **High-Yield Clinical Pearls for NEET-PG:** * **MDS Hallmark:** "Hypercellular marrow with peripheral cytopenia" [2]. * **Pseudo-Pelger-Huët Anomaly:** Hyposegmented neutrophils, a classic dysplastic feature in MDS [2]. * **Ring Sideroblasts:** Visualized using **Perls' Prussian Blue stain**; they represent iron-laden mitochondria encircling the nucleus. * **Transformation:** MDS carries a high risk of transforming into **Acute Myeloid Leukemia (AML)**, whereas CML typically progresses to a **Blast Crisis** [1][2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of White Blood Cells, Lymph Nodes, Spleen, and Thymus, pp. 624-625. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 613-614.

Practice by Chapter

Anemias: Classification and Approach

Practice Questions

Hemolytic Anemias

Practice Questions

Myeloproliferative Neoplasms

Practice Questions

Myelodysplastic Syndromes

Practice Questions

Acute Leukemias

Practice Questions

Chronic Leukemias

Practice Questions

Lymphomas and Lymphoid Neoplasms

Practice Questions

Plasma Cell Disorders

Practice Questions

Bleeding Disorders

Practice Questions

Thrombotic Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free